All In Biotech

Drug Trial Radar · NCT06508684

Current Status of BTKi Treatment for CLL/SLL in China

Current Status and Influencing Factors of Chinese Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Undergoing Treatment With Bruton's Tyrosine Kinase Inhibitors

Last checked: Nov 20, 2026Latest source record: Jul 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

1,000

Planned (sponsor's estimate)

Start

Jul 13, 2024

Primary completion

Feb 12, 2025

Study completion Jul 12, 2025

Sponsor

Sponsor type
Academic, hospital or other
First posted
Jul 18, 2024

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

BTKi has become the standard treatment regimen for CLL/SLL,there is a lack of large-scale real-world studies on the use status and related influencing factors of BTK inhibitors. Therefore, we plan to conduct this multicenter retrospective cross-sectional study to understand the current situation of BTK inhibitor treatment for CLL/SLL patients in China and the related influencing factors, and to explore more suitable treatment patterns based on this.

Conditions

  • CLL/SLL

Interventions

  • BTK inhibitorDrug

    BTKi can refer to Orelabrutinib, Ibrutinib, Zanubrutinib, and Acalabrutinib

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Patient characteristics of those receiving BTKi treatmentTime frame: up to one year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Department of Haematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital

    Nanjin, Jiangsu, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.